-
Read more: FDA Greenlights Pivotal Study of PRECISIS’ Minimally Invasive Brain-Stimulation Therapy for Drug-Resistant Epilepsy
Heidelberg
Published:FDA Greenlights Pivotal Study of PRECISIS’ Minimally Invasive Brain-Stimulation Therapy for Drug-Resistant Epilepsy
PRECISIS, a German neurotechnology company developing minimally invasive brain-stimulation therapies, has received FDA authorization to begin a pivotal clinical trial of its EASEE® system for drug-resistant focal epilepsy – a step that moves the company closer to entering the U.S. market. The pivotal study, following the device’s Breakthrough Designation, will evaluate safety and efficacy in…
-
Read more: European Investment Bank Backs Precisis with €20M Loan to Advance Breakthrough Neurostimulation Therapy in UK, Europe and US Markets
Published:European Investment Bank Backs Precisis with €20M Loan to Advance Breakthrough Neurostimulation Therapy in UK, Europe and US Markets
Heidelberg/Berlin, July 24 2025. Precisis, a Heidelberg-based MedTech innovator developing personalized neurostimulation technology for neurological disorders, announced today the closing of a €20 million venture loan from the European Investment Bank (EIB). This funding complements the company’s recently started efforts to raise an additional €37 million in equity financing as part of its Series B…
-
Read more: 150 Patients – 150 Times New Hope
Published:150 Patients – 150 Times New Hope
We at PRECISIS are proud to announce a major milestone: 150 patients implanted with EASEE® across Europe. This achievement marks a significant step forward in our mission to improve the lives of people living with drug-resistant focal epilepsy. EASEE®, which received its CE mark in September 2022, is now actively implanted by leading epileptologists and neurosurgeons in…
News
Bright Prospects for the Future.
Read about our progress and milestones, our expansions and experts, our commitment and dialogue—in short: everything that drives us.
Discover more from PRECISIS
PRECISIS GmbH, based in Heidelberg, develops bioelectronic therapies that target the very source of neurological diseases – the brain itself. Learn more about our technology, our team, and the vision behind EASEE®.